About UsNo New HIV Infections Among Kaiser PrEP Users, But Cascade Shows Missed Opportunities
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Thursday, 21 September 2017 00:00
- Written by Liz Highleyman
No new HIV infections have occurred among nearly 5000 people who started Truvada for pre-exposure prophylaxis (PrEP) in the Kaiser Permanente Northern California health system, according to a letter in the July 29 edition of Clinical Infectious Diseases.
IAS 2017: Experts Agree that Intermittent Oral PrEP Probably Won't Work for Women
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Thursday, 21 September 2017 00:00
- Written by Gus Cairns
Two presenters at the recent International AIDS Society Conference on HIV Science (IAS 2017) in Paris told delegates that both trial results and analysis of drug levels support the idea that event-related or "on demand" pre-exposure prophylaxis (PrEP) might not be sufficiently powerful to prevent HIV infection in women and trans men via vaginal sex.
San Francisco Annual Report Shows Continued Drop in HIV Infections
- Details
- Category: HIV/AIDS Epidemiology & Mortality
- Published on Wednesday, 20 September 2017 00:00
- Written by Liz Highleyman
The San Francisco Department of Public Health has released its HIV Epidemiology Annual Report for 2016, showing that the number of new infections continues to decline, with decreases seen across demographic groups. Homeless people, however, have higher rates of infection and poorer treatment outcomes.
IAS 2017: Switch from Boosted Protease Inhibitor to Dolutegravir Reduces Lipids in People with HIV
- Details
- Category: HIV Treatment
- Published on Thursday, 21 September 2017 00:00
- Written by Keith Alcorn
Switching from a boosted protease inhibitor to the integrase inhibitor dolutegravir (Tivicay) was associated with lipid reductions in people with HIV at higher risk of heart disease, according to results of the NEAT 022 study presented at the recent 9th International AIDS Society Conference on HIV Science (IAS 2017) in Paris.
IAS 2017: Doravirine Combo Pill Looks Good for Initial HIV Treatment
- Details
- Category: HIV Treatment
- Published on Thursday, 17 August 2017 00:00
- Written by Liz Highleyman
A single-tablet regimen containing the next-generation NNRTI doravirine reduced HIV viral load as much as an efavirenz-based coformulation, but it had a more favorable side effect profile, according to results from the DRIVE-AHEAD studypresented at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.
IAS 2017: Who Are Trans Women Acquiring HIV From?
- Details
- Category: Transgender People
- Published on Thursday, 21 September 2017 00:00
- Written by Gus Cairns
There is a lot we don't know about trans women's HIV risk, why they are so vulnerable to HIV, and who trans women are acquiring HIV from. A study presented at the recent 9th International AIDS Society Conference on HIV Science (IAS 2017) attempted to answer these questions, but in the process uncovered another mystery: is there a hidden population of heterosexual men who have sex with trans women and who are themselves at high risk of acquiring and transmitting HIV? One thing the study did make clear, however, is that a lot of HIV infections among trans women may be due to injecting drugs rather than sex.
IAS 2017: Boosted Darunavir Plus Lamivudine Matches 3-Drug Regimen
- Details
- Category: HIV Treatment
- Published on Thursday, 17 August 2017 00:00
- Written by Keith Alcorn
A combination of darunavir/ritonavir and lamivudine was just as effective as the same combination plus tenofovir, according to 24-week results from the ANDES study, presented at the recent 9th IAS Conference on HIV Science (IAS 2017) in Paris.
CDC Continues to Recommend Annual HIV Testing for Gay Men
- Details
- Category: HIV Testing & Diagnosis
- Published on Thursday, 21 September 2017 00:00
- Written by Liz Highleyman
The U.S. Centers for Disease Control and Prevention (CDC) recently reaffirmed its recommendation that sexually active gay and bisexual men should undergo at least annual HIV screening, according to a report in the August 11 edition of the CDC's Morbidity and Mortality Weekly Report. However, some local providers advise more frequent HIV and sexually transmitted infection tests.
IAS 2017: PrEP Use in U.S. Exceeds 100,000 in Gilead Pharmacy Survey
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Thursday, 17 August 2017 00:00
- Written by Liz Highleyman
An estimated 120,000 people in the U.S. have started Truvada (tenofovir/emtricitabine) for pre-exposure prophylaxis (PrEP) since 2012, according to the latest findings from a survey of retail and mail-order pharmacies by Gilead Sciences, presented at the recent 9th IAS Conference on HIV Science (IAS 2017) in Paris.
Web Design and Development by